Zurcher Kantonalbank (Zurich Cantonalbank) Clovis Oncology, Inc. Transaction History

Zurcher Kantonalbank (Zurich Cantonalbank)

$32.8 Billion
Q3 2024

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 09, 2022	SELL	$0.63 - $2.96 $8,259 - $38,808	-13,111 Closed	0 $0
Q2 2020 Jul 28, 2020	BUY	$5.69 - $9.69 $74,601 - $127,045	13,111 New	13,111 $88,000
Q4 2019 Jan 21, 2020	SELL	$3.0 - $16.43 $8,262 - $45,248	-2,754 Closed	0 $0
Q1 2019 Apr 29, 2019	SELL	$17.66 - $30.28 $6,887 - $11,809	-390 Reduced 12.4%	2,754 $68,000
Q3 2018 Nov 09, 2018	BUY	$29.37 - $49.48 $16,124 - $27,164	549 Added 21.16%	3,144 $92,000
Q4 2017 Jan 31, 2018	BUY	$57.69 - $84.58 $44,767 - $65,634	776 Added 42.66%	2,595 $176,000
Q3 2017 Nov 08, 2017	BUY	$67.17 - $84.81 $122,182 - $154,269	1,819	1,819 $150,000

Others Institutions Holding CLVS

# of Institutions

Shares Held

166

Call Options Held

Put Options Held

Exane Derivatives

166
Shares

$14
0.0% of portfolio

View Full List

About Clovis Oncology, Inc.

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

More about CLVS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Zurcher Kantonalbank (Zurich Cantonalbank), based on Form 13F filings with the SEC.

News

Stay updated on Zurcher Kantonalbank (Zurich Cantonalbank) with notifications on news.

Account